Difference between revisions of "Cixutumumab (IMC-A12)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.ncbi" to "[https://www.ncbi") |
||
| Line 13: | Line 13: | ||
===[[Thymoma]]=== | ===[[Thymoma]]=== | ||
| − | # '''NCI 09-C-0212:''' Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014 Feb;15(2):191-200. Epub 2014 Jan 15. [https://doi.org/10.1016/s1470-2045(13)70596-5 link to original article] [ | + | # '''NCI 09-C-0212:''' Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014 Feb;15(2):191-200. Epub 2014 Jan 15. [https://doi.org/10.1016/s1470-2045(13)70596-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3954701/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24439931/ PubMed] |
==Also known as== | ==Also known as== | ||
Latest revision as of 23:51, 6 July 2024
Mechanism of action
Monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R).
Preliminary data
Adrenocortical carcinoma
- Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013 Mar 5;108(4):826-30. Epub 2013 Feb 14. link to original article link to PMC article PubMed
Ewing sarcoma
- Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012 May 1;18(9):2625-31. Epub 2012 Mar 31. link to original article link to PMC article PubMed
Soft tissue sarcoma
- NCI-2011-01408: Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr;14(4):371-82. Epub 2013 Mar 8. link to original article link to PMC article PubMed NCT01016015
Thymoma
- NCI 09-C-0212: Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014 Feb;15(2):191-200. Epub 2014 Jan 15. link to original article link to PMC article PubMed
Also known as
- Code name: IMC-A12